Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda hires compliance officer

Executive Summary

Takeda Pharmaceuticals has hired Jeanine Jiganti as the company's chief compliance officer. Jiganti, formerly with the Illinois Department of Commerce and Economic Opportunity, will advise senior management on compliance and regulatory issues and promote compliance with applicable laws and company policies. Takeda's joint venture with Abbott, TAP, reached a settlement with federal prosecutors in 2001 to resolve allegations of violations of the Prescription Drugs Marketing Act and the False Claims Act (1"The Pink Sheet" July 19, 2004, p. 14)...

You may also be interested in...



TAP Execs Acquitted Of Conspiracy Charges Related To Marketing Practices

The acquittal of eight current and former TAP employees on conspiracy charges suggests that the perception of shifting standards for marketing compliance will make it difficult for prosecutors to translate corporate settlements into convictions of individual executives

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.

Topics

UsernamePublicRestriction

Register

OM007836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel